Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−6.72 EUR
−141.58 M EUR
0.00 EUR
6.45 M
About Seres Therapeutics, Inc.
Sector
Industry
Website
Headquarters
Cambridge
Founded
2010
ISIN
US81750R2013
FIGI
BBG01JYWSP03
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Related stocks
MCRB Triangle Symmetrical Top (bullish)I found this pattern at tickeron website with the following data:
STATUS = Confirmed
CURRENT CONFIDENCE = 88%
TARGET (EXIT) PRICE = 34.49 USD
BREAKOUT (ENTRY) PRICE = 28.53 USD
DISTANCE TO TARGET PRICE = 18.93%
EMERGED ON = Sep 10, 12:00 PM (EDT)
CONFIRMED ON = Sep 29, 10:10 AM (EDT)
WITH CONFIDENCE
pssh im waiting until tomorrow :)its looking like about $15 to $16 a share tomorrow at the low before liftoff
Using Sine waves and Fibonacci Spirals to help find the low point on this current "high rise" still a bear market if you ask 2016 i think. . well at least until another one of them thar peaks coming up awful quickly :)
Positive Topline Results from SER-109 Phase 3Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
– SER-109 met Phase 3 primary endpoint, showing a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo –
– SER-109 was well
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
The current price of 1S90 is 15.58 EUR — it has decreased by −3.00% in the past 24 hours. Watch Seres Therapeutics Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Seres Therapeutics Inc stocks are traded under the ticker 1S90.
1S90 stock has fallen by −2.88% compared to the previous week, the month change is a 24.16% rise, over the last year Seres Therapeutics Inc has showed a 76.07% increase.
We've gathered analysts' opinions on Seres Therapeutics Inc future price: according to them, 1S90 price has a max estimate of 17.09 EUR and a min estimate of 11.96 EUR. Watch 1S90 chart and read a more detailed Seres Therapeutics Inc stock forecast: see what analysts think of Seres Therapeutics Inc and suggest that you do with its stocks.
1S90 reached its all-time high on Aug 26, 2025 with the price of 17.36 EUR, and its all-time low was 5.94 EUR and was reached on May 9, 2025. View more price dynamics on 1S90 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1S90 stock is 3.23% volatile and has beta coefficient of 1.54. Track Seres Therapeutics Inc stock price on the chart and check out the list of the most volatile stocks — is Seres Therapeutics Inc there?
Today Seres Therapeutics Inc has the market capitalization of 138.92 M, it has decreased by −2.05% over the last week.
Yes, you can track Seres Therapeutics Inc financials in yearly and quarterly reports right on TradingView.
Seres Therapeutics Inc is going to release the next earnings report on Nov 18, 2025. Keep track of upcoming events with our Earnings Calendar.
1S90 earnings for the last quarter are −1.93 EUR per share, whereas the estimation was −2.11 EUR resulting in a 8.84% surprise. The estimated earnings for the next quarter are 0.38 EUR per share. See more details about Seres Therapeutics Inc earnings.
Seres Therapeutics Inc revenue for the last quarter amounts to 0.00 EUR, despite the estimated figure of 0.00 EUR. In the next quarter, revenue is expected to reach 6.72 M EUR.
1S90 net income for the last quarter is −16.85 M EUR, while the quarter before that showed 30.21 M EUR of net income which accounts for −155.79% change. Track more Seres Therapeutics Inc financial stats to get the full picture.
No, 1S90 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 4, 2025, the company has 103 employees. See our rating of the largest employees — is Seres Therapeutics Inc on this list?
Like other stocks, 1S90 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Seres Therapeutics Inc stock right from TradingView charts — choose your broker and connect to your account.